Regulation of transient receptor potential ankyrin-1 agonist–induced airway epithelial cell injury and repair by protein kinase C and p38 mitogen-activated kinase
Publication date: October 2026 Source: Molecular Pharmacology, Volume 108, Issue 10 Author(s): Samantha N. Serna, Erin G. Romero, Shao-En Ong, Martin Golkowski, Lili Sun, Christopher A. Reilly
Regulation of transient receptor potential ankyrin-1 agonist–induced airway epithelial cell injury and repair by protein kinase C and p38 mitogen-activated kinase. // Molecular Pharmacology. – URL: https://www.sciencedirect.com/science/article/pii/S0026895X26000532?dgcid=rss_sd_all
Regulation of transient receptor potential ankyrin-1 agonist–induced airway epithelial cell injury and repair by protein kinase C and p38 mitogen-activated kinase. Molecular Pharmacology. https://www.sciencedirect.com/science/article/pii/S0026895X26000532?dgcid=rss_sd_all
“Regulation of transient receptor potential ankyrin-1 agonist–induced airway epithelial cell injury and repair by protein kinase C and p38 mitogen-activated kinase.” Molecular Pharmacology.
@article{article59050,
title = {Regulation of transient receptor potential ankyrin-1 agonist–induced airway epithelial cell injury and repair by protein kinase C and p38 mitogen-activated kinase},
journal = {Molecular Pharmacology},
url = {https://www.sciencedirect.com/science/article/pii/S0026895X26000532?dgcid=rss_sd_all}
}
Acta Pharmacologica Sinica, Published online: 16 November 2026; doi:10.1038/s41401-026-01953-z IRAK4 inhibitor DW18134 ameliorates diffuse large B-cell lymphoma in combination with ibrutinib and overcomes acquired resistance to ibrutinib
Acta Pharmacologica Sinica, Published online: 16 November 2026; doi:10.1038/s41401-026-01958-8 Artificial intelligence aids multi-omics data integration in cancer drug discovery and development: from targets to drug synergy
Nature Reviews Drug Discovery, Published online: 13 November 2026; doi:10.1038/d41573-026-00179-2 The NIH’s P. J. Brooks discusses the challenges and opportunities ahead for gene therapies and gene editing for diseases of no commercial interest.
Nature Reviews Drug Discovery, Published online: 13 November 2026; doi:10.1038/d41573-026-00181-8 Merck and Moderna’s intismeran autogene succeeded in a landmark melanoma trial, but the oncology community still has more questions than...